GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » EV-to-FCF

Marksans Pharma (NSE:MARKSANS) EV-to-FCF : (As of May. 12, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Marksans Pharma's Enterprise Value is ₹66,560 Mil. Marksans Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0 Mil. Therefore, Marksans Pharma's EV-to-FCF for today is .

The historical rank and industry rank for Marksans Pharma's EV-to-FCF or its related term are showing as below:

NSE:MARKSANS' s EV-to-FCF Range Over the Past 10 Years
Min: 0   Med: 0   Max: 40.52
Current: 36.22

During the past 13 years, the highest EV-to-FCF of Marksans Pharma was 40.52. The lowest was 0.00. And the median was 0.00.

NSE:MARKSANS's EV-to-FCF is ranked worse than
66.73% of 511 companies
in the Drug Manufacturers industry
Industry Median: 23.55 vs NSE:MARKSANS: 36.22

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Marksans Pharma's stock price is ₹159.25. Marksans Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.070. Therefore, Marksans Pharma's PE Ratio for today is 22.52.


Marksans Pharma EV-to-FCF Historical Data

The historical data trend for Marksans Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma EV-to-FCF Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.12 2.99 14.28 31.12 14.00

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.00 - - -

Competitive Comparison of Marksans Pharma's EV-to-FCF

For the Drug Manufacturers - General subindustry, Marksans Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's EV-to-FCF falls into.



Marksans Pharma EV-to-FCF Calculation

Marksans Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=66559.927/0
=

Marksans Pharma's current Enterprise Value is ₹66,560 Mil.
Marksans Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma  (NSE:MARKSANS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Marksans Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=159.25/7.070
=22.52

Marksans Pharma's share price for today is ₹159.25.
Marksans Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7.070.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Marksans Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines